Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease allergic bronchopulmonary aspergillosis
Comorbidity C0010674|cystic fibrosis
Sentences 29
PubMedID- 26003072 The classic diagnostic criteria of allergic bronchopulmonary aspergillosis in cystic fibrosis have been established during the cystic fibrosis foundation conference in 2001.
PubMedID- 25015245 [role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis].
PubMedID- 24735832 Other consensus reviews and statements relevant to this topic have described the status of allergic bronchopulmonary aspergillosis (abpa) in cystic fibrosis [3], lower airways interaction with fungi and its clinical consequences [4] and the whole topic of abpa [5], the last with recommendations for a new definition of abpa.
PubMedID- 25150265 Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 22696329 Antifungal therapy for abpa in cystic fibrosis needs to be evaluated.
PubMedID- 20127304 Typical acute complications are infective exacerbations - the most frequent cause of death in cystic fibrosis - along with allergic bronchopulmonary aspergillosis, haemoptyses and pneumothoraces.
PubMedID- 26005342 abpa classically occurs in patients with asthma or cystic fibrosis, but cases in patients with copd or non-cystic fibrosis bronchiectasis have also been described.
PubMedID- PMC4406118 It is known that cystic fibrosis together with abpa will induce a more significant deterioration of the lung function than either alone and seriously interferes with quality of life.
PubMedID- 22731696 It is conceivable that high il-10 levels could contribute to the resolution of the aspergillus induced pulmonary inflammation, but high il-10 concentrations have also been associated with development of invasive aspergillosis in non-neutropenic immunocompromised patients and with colonization with a. fumigatus and allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [26].
PubMedID- 22448043 Airway colonization with aspergillus causes allergic bronchopulmonary aspergillosis (abpa) in patients with cystic fibrosis or chronic asthma.
PubMedID- 20714107 Vitamin d3 attenuates th2 responses to aspergillus fumigatus mounted by cd4+ t cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis.
PubMedID- 21246055 The ubiquitous fungus aspergillus fumigatus is associated with chronic diseases such as invasive pulmonary aspergillosis in immunosuppressed patients and allergic bronchopulmonary aspergillosis (abpa) in patients with cystic fibrosis or severe asthma.
PubMedID- 24167019 Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence.
PubMedID- 23118662 Conflicting reports exist about the effects of omalizumab on abpa in patients with cystic fibrosis (cf).
PubMedID- 22794691 The key to early diagnosis is considering abpa in anyone with asthma or cystic fibrosis and a positive skin test to aspergillus and /or recurrent infiltrates on radiographs.
PubMedID- 22608296 Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens.
PubMedID- 23204847 There are reports of the steroid-sparing effect of anti-ige therapy with omalizumab for abpa in patients with cystic fibrosis (cf), but there is little information on its efficacy against abpa in patients with bronchial asthma without cf.
PubMedID- 24043500 Therefore, anti-ige therapy, using agents like omalizumab, may be a potential therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
PubMedID- 25354514 allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 23278646 Hla-drb1 and hla-dqb1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
PubMedID- 26187954 allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated.
PubMedID- 23632183 The aim of the paper is to report the case of a boy affected by cystic fibrosis, with non-abpa-related recurrent wheezing and frequent pulmonary exacerbation during childhood, who had been inhaling 7% nacl+0.1% hyaluronic acid (ha) as a maintenance therapy.
PubMedID- 23278535 Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease.
PubMedID- 21067334 Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges.
PubMedID- 19804448 Steroid dependency despite omalizumab treatment of abpa in cystic fibrosis.
PubMedID- 25010610 Anti ige antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis.
PubMedID- 20178634 Other conditions reported to show elevated ige levels include cystic fibrosis [94] (with associated abpa-like disease, probably secondary to increased airway penetration by allergen), nicotine abuse [95] and pulmonary hemosiderosis (heiner's syndrome)[96].
PubMedID- 20597074 Risk factors for aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis.
PubMedID- 25753544 Allergic broncho-pulmonary aspergillosis (abpa) affects patients with asthma or cystic fibrosis.

Page: 1